Functional recovery in parkinsonian monkeys treated with GDNF

[1]  John L. Hudson,et al.  Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo , 1995, Brain Research Bulletin.

[2]  B J Hoffer,et al.  Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys , 1995, The Journal of comparative neurology.

[3]  Don M. Gash,et al.  Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys , 1995, Neurobiology of Aging.

[4]  A. Granholm,et al.  Glial cell line‐derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons , 1995, The Journal of comparative neurology.

[5]  K. Double,et al.  Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Gash,et al.  GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo , 1995, Brain Research.

[7]  R. Vandlen,et al.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.

[8]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[9]  John L. Hudson,et al.  Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo , 1994, Neuroscience Letters.

[10]  R. Kurlan,et al.  Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.

[11]  G. M. Halliday,et al.  Practical considerations for the use of the optical disector in estimating neuronal number , 1994, Journal of Neuroscience Methods.

[12]  M. Sofroniew,et al.  Trophism, Transplantation, and Animal Models of Parkinson's Disease , 1993, Experimental Neurology.

[13]  Mark J. West,et al.  New stereological methods for counting neurons , 1993, Neurobiology of Aging.

[14]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[15]  Z. Zhang,et al.  Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.

[16]  Richard E. Coggeshall,et al.  A consideration of neural counting methods , 1992, Trends in Neurosciences.

[17]  M. Delong,et al.  Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.

[18]  H. Robertson,et al.  Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  G. Robertson,et al.  Evidence that the substantia nigra is a site of action for l-DOPA , 1988, Neuroscience Letters.

[20]  K. Jellinger,et al.  Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.

[21]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[22]  D. Jacobowitz,et al.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.